Kimberly Sackheim
Interventional Pain Medicine · New York, NYNPI 1801056551
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,775 of the $102,095 with a category attached, or 74.2%. 29 manufacturers reported payments, led by AbbVie at 29.6% of the total. Reporting peaked in 2019 at $51,187 and has fallen 98.5% since, to $780 in 2025. Among interventional pain medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 444 payments — averaging $229.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$30K
- Amgen$30K
- Daiichi Sankyo Inc.$22K
- Teva Pharmaceuticals USA, Inc.$15K
- Biohaven Pharmaceuticals, Inc.$1K
- Stryker$939
- plus $3K from 23 others
What the payments were for
- Consulting fees$6,9507%
- Speaking & faculty fees$75,77574%
- Travel & lodging$8,9599%
- Food & beverage$10,29710%
- Education$1130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 157 | $30,188 |
| Amgen(2 entities) | 54 | $29,515 |
| Daiichi Sankyo Inc. | 31 | $21,652 |
| Teva Pharmaceuticals USA, Inc. | 48 | $15,003 |
| Biohaven Pharmaceuticals, Inc. | 11 | $1,487 |
| Stryker | 3 | $939 |
| Collegium Pharmaceutical, Inc. | 31 | $611 |
| Pfizer | 29 | $505 |
| Medtronic(2 entities) | 5 | $442 |
| Biohaven Pharmaceutical Holding Company Ltd. | 25 | $316 |
| Almatica Pharma LLC | 11 | $237 |
| Lundbeck LLC | 12 | $229 |
| Novartis | 4 | $182 |
| Lilly USA, LLC | 4 | $178 |
| Johnson & Johnson | 3 | $142 |
| Saluda Medical Americas, Inc. | 1 | $122 |
| Tonix Medicines, Inc. | 1 | $84 |
| Vertex | 2 | $44 |
| Assertio Therapeutics, Inc. | 2 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $23 |
| Upsher-smith Laboratories LLC | 1 | $22 |
| Novo Nordisk | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Pacira Therapeutics, Inc. | 1 | $18 |
| Forte Bio-pharma LLC | 1 | $14 |
| Fidia Pharma USA Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIMOVIG$28,902
- UBRELVY$27,131
- Morphabond ER$21,391
- AJOVY$14,188
- NURTEC ODT$1,250
- IVS - VERTEBRAL AUGMENTATION PRODUCTS$763
- BOTOX$547
- RAYOS$388
- SPINEJACK$176
- IVS - AVA$176
- INTELLIS ADAPTIVESTIM$149
- VANTA ADAPTIVESTIM$130
- Evoke$122
- ADAPTIVESTIM$119
- VYEPTI$116
How this compares
$102,095 in reported general payments places this provider in the 95th percentile of 132 interventional pain medicine providers in New York.
See all interventional pain medicine providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 27 | $2,660 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 28 | $879 |
| Gabapentin | 33 | $276 |
| Morphine Sulfate | 11 | $235 |
| Pregabalin | 12 | $210 |
| Hydromorphone Hcl | 11 | $107 |
| Alprazolam | 13 | $76 |
| Oxycodone Hcl | 22 | $71 |
| Tramadol Hcl | 12 | $28 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAMorphine Sulfate | $23 | $23511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 132 interventional pain medicine providers in New York.
Other interventional pain medicine in New York
- Corey HunterNew York$446K
- Neel MehtaNew York$432K
- Suelane OuroNew York$68K
- Gerard DegregorisNew York$49K
- Marco PappagalloNew York$36K
- Jason SieffermanNew York$29K
- Barthelemy LiabaudNew York$20K
- Devi NampiaparampilNew York$18K
- Jeffrey DeygooNew York$11K
- Imran PunekarNew York$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.